These results were in line with associations described between high CXCR4 expression and poor outcome in patients with rhabdomyosarcoma [21] and synovial sarcoma [29,48], and in a 12-study meta-analysis of bone sarcomas and STSs [19]. Here, CXCR4 is linked to synovial sarcoma.